微芯生物(688321.SH)：CS08399片临床试验申请获得受理

Core Viewpoint - Micron Biomedical (688321.SH) has received the acceptance notice for the clinical trial application of its self-developed CS08399 tablets from the National Medical Products Administration (NMPA) for the treatment of solid tumors and lymphomas with methionine adenosine phosphorylase (MTAP) deficiency [1] Group 1 - The clinical trial application is specifically aimed at treating solid tumors and lymphomas associated with MTAP deficiency [1]